Abstract
The Epidermal growth factor receptor (EGFR) family plays an important role in carcinogenesis. CIMAher® (Nimotuzumab), is a humanized monoclonal antibody, which recognizes EGFR with high affinity. The aim of this work was to perform the direct labeling of Nimotuzumab with [99mTc(CO)3(H2O)3]+ as precursor and to evaluate its labeling conditions, in vitro and in vivo stability and biodistrution in normal C57 BL/6J mice. 99mTc(CO3)-Nimotuzumab labeling yields were up to 90%. More than 90% of the complex remained intact after 24 h of incubation with L-Histidine (1/300 molar ratio). Biodistribution studies in normal mice were also performed. Inmunoreactivity was confirmed by cell binding assays with A431cells. These results encourage the evaluation of the potential role of 99mTc(CO3)-Nimotuzumab as a novel tumor-avid radiotracer for targeting in vivo EGFR expression.
Keywords: 99m-Technetium, Nimotuzumab, EGFR, tricarbonyl, Epidermal growth factor receptor
Current Radiopharmaceuticals
Title: Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Volume: 5 Issue: 1
Author(s): Maria Fernanda Garcia, Ximena Camacho, Victoria Calzada, Marcelo Fernandez, Williams Porcal, Omar Alonso, Juan Pablo Gambini and Pablo Cabral
Affiliation:
Keywords: 99m-Technetium, Nimotuzumab, EGFR, tricarbonyl, Epidermal growth factor receptor
Abstract: The Epidermal growth factor receptor (EGFR) family plays an important role in carcinogenesis. CIMAher® (Nimotuzumab), is a humanized monoclonal antibody, which recognizes EGFR with high affinity. The aim of this work was to perform the direct labeling of Nimotuzumab with [99mTc(CO)3(H2O)3]+ as precursor and to evaluate its labeling conditions, in vitro and in vivo stability and biodistrution in normal C57 BL/6J mice. 99mTc(CO3)-Nimotuzumab labeling yields were up to 90%. More than 90% of the complex remained intact after 24 h of incubation with L-Histidine (1/300 molar ratio). Biodistribution studies in normal mice were also performed. Inmunoreactivity was confirmed by cell binding assays with A431cells. These results encourage the evaluation of the potential role of 99mTc(CO3)-Nimotuzumab as a novel tumor-avid radiotracer for targeting in vivo EGFR expression.
Export Options
About this article
Cite this article as:
Fernanda Garcia Maria, Camacho Ximena, Calzada Victoria, Fernandez Marcelo, Porcal Williams, Alonso Omar, Pablo Gambini Juan and Cabral Pablo, Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies, Current Radiopharmaceuticals 2012; 5 (1) . https://dx.doi.org/10.2174/1874471011205010059
DOI https://dx.doi.org/10.2174/1874471011205010059 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Tankyrase Inhibitors as Therapeutic Targets for Cancer
Current Topics in Medicinal Chemistry Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Current Topics in Medicinal Chemistry Cellular Efflux of cAMP and cGMP - A Question about Selectivity
Mini-Reviews in Medicinal Chemistry Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Trends in Malignant Glioma Monoclonal Antibody Therapy
Current Cancer Therapy Reviews Medicinal and Cosmetic Potentials of Sophorolipids
Mini-Reviews in Medicinal Chemistry Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Application of Targeted Therapy to Malignant Gliomas and Response to Treatment
Current Signal Transduction Therapy GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Intracellular Signaling Pathways Modulated by Phenolic Compounds: Application for New Anti-Inflammatory Drugs Discovery
Current Medicinal Chemistry The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets